This study will assess minimal residual disease (MRD) in HER2-positive early breast cancer patients in Asian countries. The purpose is to evaluate the relation between the detection rate of MRD and recurrence.
Age of 20 years or older at the date of registration.
Histological diagnosis of HER2-positive invasive breast carcinoma.
Patients scheduled for neoadjuvant chemotherapy followed by surgery.
Clinical Stage IIA-IIIC.
Any other malignancy within 5 years prior to registration, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the esophagus, stomach, colon, or cervix.
Bilateral synchronous breast cancer.
History of breast cancer.
Pregnancy at registration.
Map coordinates are unavailable for these locations. Locations are shown below instead.
Japan